Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants

September 2022

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Patients are returning to doctors’ offices, but not at the same rates prior to the COVID-19 pandemic. During the pandemic, in-person visits to healthcare professionals (HCPs) saw a dramatic reduction. This resulted in fewer diagnoses, which inevitably led to a reduction in the number of new prescriptions and therapy starts.

During this same time period, however, drug companies launched a higher-than-average number of new products. With fewer patients to prescribe to, many products struggled to gain attention and recognition. Even as HCP visits return to close to pre-pandemic levels, patients are being diagnosed further along in their illnesses then they normally would be, which is altering the therapies being prescribed to them.

Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants (pharmexec.com)

Kommentar

Teilen